<DOC>
	<DOCNO>NCT00181142</DOCNO>
	<brief_summary>The purpose study compare outcomes patient undergo lung transplantation , use 2 different induction therapy . Primary outcome survival secondary outcome include freedom infection freedom rejection .</brief_summary>
	<brief_title>The Use Daclizumab Anti-Thymocyte Globulin Lung Transplantation</brief_title>
	<detailed_description>Acute chronic allograft rejection two common problem limit complicate utility lung transplantation . The timing frequency acute rejection show significant risk factor development chronic allograft rejection . As adjunct standard triple immunosuppressive therapy , induction therapy think decrease incidence acute rejection.Daclizumab interleukin 2 receptor ( IL-2 ) antagonist FDA approve immunosuppressive agent . Thymoglobulin anti-lymphocyte immunosuppressive agent show solid organ transplant study successful delay first episode rejection decrease incidence Obliterative Bronchiloitis ( chronic rejection ) lung transplantation .</detailed_description>
	<mesh_term>Daclizumab</mesh_term>
	<criteria>All patient accept listed lung transplantation consider randomization Patients demonstrate hemodynamic instability , require inotropes great 48 hour prior transplant Severe reperfusion pulmonary edema primary graft dysfunction require FiO2 &gt; 50 % PEEP &gt; 10 cm great 48 hour prior transplant Preoperative renal insufficiency ( CrCl &lt; 50 gm.d serum creatinine &gt; 2.0 ) Preoperative panel reactive antibody PRA Preoperative recipient bacterial fungal colonization Preoperative antimicrobial suppressive therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>66 Years</maximum_age>
	<verification_date>August 2004</verification_date>
	<keyword>Induciton therapy , Daclizumab , Thymoglobulin , lung transplantation</keyword>
</DOC>